FOLFIRINOX in borderline resectable pancreatic carcinoma

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter E. Una Cidon
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors E. Una Cidon1, P. Alonso2
  • 1Oncology Department, Royal Bournemouth Hospital, NHS Foundation Trust, Bournemouth, United Kingdom, /
  • 2Clinical University Hospital, Valladolid, Spain, /

Abstract

Borderline resectable pancreatic cancer needs to be treated by multimodality therapies. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) has shown effectiveness in the treatment of this disease by increasing response rate with an impact on median survival. Toxicity could be concerning but supportive measures can help significantly.